Zymeworks discontinues ZW171 Phase 1 after dose escalation; benefit-risk profile unfavorable

Zymeworks Inc.

Decision based on completed dose escalation in ovarian and NSCLC patients; MTD established but benefit-risk not supportive.
Dose-limiting toxicities consistent with mesothelin-related on-target off-tumor toxicity; CRS was well-managed.
Ongoing participants may continue at investigator discretion; discontinued patients remain in safety follow-up.
Pipeline continues: ZW191 Phase 1 ongoing, ZW251 Phase 1 expected 2025, ZW209 IND filing planned H1 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.